Loading…
Phibro Animal Health Corporation
NASDAQ: PAHC Healthcare Pharma 🔎 Screen
$1.5B
Market Cap
21.5
P/E
0.52
PEG
18.3%
ROCE
17.8%
ROE
2.46
D/E
8.5%
OPM
-39.2%
% from 52W High
75
α RS
🔍 PAHC is showing a sector-leadership setup because Sector RRG has Health Care in the Leading quadrant with the trail still rolling over, it matches 2 of 37 tracked screener presets, and RS Rating is 75. Net: Broad signal stack, not a recommendation. ? RRG Conviction RS Rating
Sources
Health Care in Leading quadrant · Conviction 2/37 · RS Rating 75
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for PAHC including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding PAHC
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 576.7K $31.9M 0.05% Mar 2026
Steve Cohen Point72 Asset Management 19.5K $1.1M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
📊 MIXED Phibro Animal Health: Q3 net sales $383.5M (+10%), Adj. EBITDA $60M (+11%)
Revenue & Profitability
Q3 2026 net sales were $383.5 million, up 10% YoY. Adjusted EBITDA increased 11% to $60 million. GAAP net income and diluted EPS increased, driven by higher gross profit. Adjusted net income and adjusted diluted EPS both rose 19%. Full-year FY2026 guidance: net sales $1.46B-$1.5B (midpoint ~14% growth), Adjusted EBITDA $247M-$255M (midpoint ~37% growth), Adjusted net income $122M-$127M.
Outlook
Management sees a complex broader protein backdrop: tight beef supply supporting prices, early dairy stabilization despite fat pressure, and positive poultry demand. Geopolitical volatility in the Middle East is a headwind. Brazil’s new antimicrobial regulatory framework is viewed as a culmination of long-running changes, not the start of a new wave, with transition expected to strengthen Phibro's position.
Growth Drivers
Key growth levers include: strong demand in North America for MFAs, nutritional specialties, and autogenous vaccines (16% vaccine growth); higher companion animal sales; and the scalable VERRATAIN sustainability platform. The new MFA business contributed $95.9 million in Q3 (25% growth). Long-term growth is expected from other portfolio areas to offset the Brazil virginiamycin headwind.
Balance Sheet & CapEx
For the 12 months ended March 31, 2026, capital expenditures were $53 million. Cash generation was $13 million of positive free cash flow over the same period. Inventory buildup occurred in advance of tariffs and to meet demand, expected to stabilize in coming quarters. The company upsized its revolver by $125 million via an oversubscribed process to enhance liquidity.
Margins
Adjusted EBITDA margin in Q3 was approximately 15.6% ($60M on $383.5M sales). Higher gross profit drove margin expansion, partially offset by higher SG&A (employee-related costs) and higher interest expense. The Brazil virginiamycin product has above-average margins. For FY2026, Adjusted EBITDA margin midpoint is roughly 16.6% (based on guidance midpoint of $251M on ~$1.48B sales). Phibro Forward initiative costs are included in GAAP net income.
Key Risks
Risks flagged include: Brazil's new antimicrobial regulations impacting virginiamycin sales ($26M in FY2025, above-average margins); geopolitical volatility and conflict in the Middle East affecting vaccine demand and shipping costs; tariff-related inventory buildup; foreign currency losses ($1.9M in Q3 vs. gains of $5.5M last year); and interest expense increases due to swap expiration. The guidance incorporates potential Middle East downside.
Generated by AI · Q3 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q3 2026 Q3 2026 2026-05-07
Q3 2026 saw 10% sales growth and 11% higher Adjusted EBITDA, led by Animal Health. FY2026 guidance was raised across all key metrics, with regulatory and geopolitical risks incorporated. New sustainability initiatives and a leadership transition were highlighted.
Q2 2026 Q2 2026 2026-02-05
Q2 saw 21% sales and 41% EBITDA growth, led by animal health and MFA integration. Fiscal 2026 guidance was raised for sales, EBITDA, and net income, reflecting strong demand and operational momentum. Leadership transition and new product launches support future growth.
Q1 2026 Q1 2026 2025-11-06
Q1 2026 saw 40% sales growth and 102% adjusted EBITDA growth, driven by animal health and MFA integration. Fiscal 2026 guidance for EBITDA and net income was raised, with continued investment in innovation and companion animal expansion.
Q4 2025 Q4 2025 2025-08-28
Q4 and FY2025 saw robust sales and EBITDA growth, led by Animal Health and the Zoetis MFA integration. FY2026 guidance projects continued double-digit growth, with Phibro Forward and full-year Zoetis contributions driving results.
Q3 2025 Q3 2025 2025-05-08
Q3 2025 saw 32% sales growth and 85% adjusted EBITDA increase, led by animal health and the Zoetis MFA integration. Fiscal 2025 guidance was raised for EBITDA and EPS, with tariff impacts expected to be manageable and strong cash flow supporting ongoing investments.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.